BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow BMRN
BioMarin Pharmaceutical Inc. (BMRN) P/E ratio
As of 16 October 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a P/E ratio of 144×. Over the past ten years it has ranged from 0.0× (March 2022) to 1,305× (November 2021); the current reading is higher than 81% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 32.7× | 11.78% |
| FY2024 | 29.2× | (73.48%) |
| FY2023 | 110× | (15.68%) |
| FY2022 | 131× | — |
| FY2021 | 0.0× | — |
| FY2020 | 18.6× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 151× | 273.18% |
| Mar 2026 | 40.4× | 23.57% |
| Dec 2025 | 32.7× | 63.99% |
| Sep 2025 | 19.9× | 24.61% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| PCVX Vaxcyte, Inc. compare | n/m |
| KRYS Krystal Biotech, Inc. compare | 38.3× |
| TECH Bio-Techne Corp compare | 62.0× |
| BMRN BioMarin Pharmaceutical Inc. | 144× |
| CORT Corcept Therapeutics Incorporated compare | 212× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)